Aytu BioPharma, Inc.

NasdaqCM:AYTU 株式レポート

時価総額：US$15.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aytu BioPharma マネジメント

マネジメント 基準チェック /24

Aytu BioPharma'sの CEO はJosh Disbrowで、 Apr2015年に任命され、 の在任期間は 9.17年です。 の年間総報酬は$ 708.00Kで、 83.3%給与と16.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.29%を直接所有しており、その価値は$ 217.59K 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と7.9年です。

主要情報

Josh Disbrow

最高経営責任者

US$708.0k

報酬総額

CEO給与比率83.3%
CEO在任期間9.2yrs
CEOの所有権1.3%
経営陣の平均在職期間1.8yrs
取締役会の平均在任期間7.9yrs

経営陣の近況

Recent updates

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Feb 14
A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts

Dec 31

Aytu BioScience completes safety study in critically ill COVID-19 patients

Dec 28

Aytu Bio raises 'bought deal' offering to $25M

Dec 11

Aytu BioScience: The Barcode King Is Poised For An Epic Breakout

Nov 12

CEO報酬分析

Aytu BioPharma の収益と比較して、Josh Disbrow の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$14m

Dec 31 2023n/an/a

-US$18m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$17m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018US$606kUS$303k

-US$10m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017n/an/a

-US$20m

Sep 30 2017n/an/a

-US$21m

Jun 30 2017US$1mUS$250k

-US$23m

報酬と市場: Joshの 総報酬 ($USD 708.00K ) は、 US市場 ($USD 667.63K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Joshの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Josh Disbrow (49 yo)

9.2yrs

在職期間

US$708,000

報酬

Mr. Joshua R. Disbrow, also known as Josh, serves as Chairman at Aytu Biopharma, Inc. He served as Chairman at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 until 2023 and...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Joshua Disbrow
Chairman & CEO9.2yrsUS$708.00k1.29%
$ 204.4k
Mark Oki
CFO, Secretary & Treasurer2.4yrsUS$522.84k0.17%
$ 27.1k
Greg Pyszczymuka
Chief Commercial Officer1.9yrsUS$540.05k0.41%
$ 64.9k
Victoria Cordova
Vice President of People & Culture1.4yrsデータなしデータなし
Jarrett Disbrow
Chief Business Officer & President of Consumer Health1.6yrsUS$793.41k0.23%
$ 36.5k
Russ McMahen
Senior Vice President of Research & Developmentno dataデータなしデータなし
Ryan Selhorn
Executive VP of Finance & Business Optimization1.6yrsデータなしデータなし

1.8yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: AYTUの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Joshua Disbrow
Chairman & CEO8.4yrsUS$708.00k1.29%
$ 204.4k
Vivian Liu
Independent Director1.9yrsUS$89.62k0.15%
$ 23.7k
John Donofrio
Lead Independent Director7.9yrsUS$90.00k0.041%
$ 6.4k
Carl Dockery
Independent Director8.2yrsUS$70.00k0.17%
$ 27.5k
Abhinav Jain
Independent Directorless than a yearUS$3.31k0.14%
$ 22.8k

7.9yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: AYTUの 取締役会 は 経験豊富 であると考えられます ( 7.9年の平均在任期間)。